Core Viewpoint - CVS Health has experienced significant selling pressure, with a 7.7% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst expectations of better-than-previously predicted earnings [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that helps identify whether a stock is oversold, with readings below 30 indicating oversold conditions [2]. - CVS has an RSI reading of 29.64, suggesting that the heavy selling may be exhausting itself, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts to raise earnings estimates for CVS, with a 0.3% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7]. - CVS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further indicating a potential turnaround [8].

Core Viewpoint - Steris (STE) has experienced significant selling pressure, declining 6% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, with analysts expecting better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - STE's current RSI reading is 27.46, suggesting that the heavy selling pressure may be exhausting itself, indicating a potential trend reversal [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for STE have increased by 0.1% over the last 30 days, which usually correlates with price appreciation in the near term [7]. - STE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

Core Viewpoint - Tandem Diabetes Care, Inc. (TNDM) has experienced a significant decline of 27% over the past four weeks, but it is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2] - TNDM's current RSI reading is 19.31, suggesting that the heavy selling pressure may be exhausting, indicating a potential bounce back towards equilibrium [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that TNDM's earnings estimates for the current year have increased by 0.6% over the last 30 days, which often correlates with price appreciation [7] - TNDM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential for a turnaround [8]

Group 1 - Abbott (ABT) has experienced a 9% decline over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for ABT is currently at 21.37, suggesting that the heavy selling pressure may be exhausting itself [5] - There is strong consensus among Wall Street analysts that ABT will report better earnings than previously predicted, with a 0% increase in the consensus EPS estimate over the last 30 days [7] Group 2 - ABT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

Core Viewpoint - New Gold (NGD) has experienced significant selling pressure, resulting in a 10% decline over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) for NGD is currently at 28.3, indicating that the stock is in oversold territory, which may suggest a reversal in trend soon [5] - RSI is a momentum oscillator that helps identify whether a stock is overbought or oversold, with readings below 30 typically indicating oversold conditions [2][3] Group 2: Fundamental Indicators - There has been a strong consensus among sell-side analysts to raise earnings estimates for NGD, leading to a 20.5% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [7] - NGD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8]

Core Viewpoint - Concentra Group (CON) has experienced significant selling pressure, resulting in a 5.8% decline over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating potential for recovery [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - CON's current RSI reading is 28.87, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5]. - RSI serves as a tool to identify potential price reversals, allowing investors to seek entry points for anticipated rebounds [3]. Group 2: Fundamental Analysis - Analysts have raised earnings estimates for CON, with a consensus EPS estimate increase of 0% over the last 30 days, which typically correlates with price appreciation [7]. - CON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

Core Viewpoint - Alvotech (ALVO) is experiencing significant selling pressure, with a 6.6% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by positive earnings expectations from Wall Street analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that helps identify whether a stock is oversold, with readings below 30 indicating oversold conditions [2]. - ALVO's current RSI reading of 28.6 suggests that the heavy selling may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts that earnings estimates for ALVO have increased by 6.3% over the last 30 days, which typically correlates with price appreciation in the near term [7]. - ALVO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further indicating a potential turnaround [8].

Core Viewpoint - Nokia (NOK) has experienced a significant downtrend with an 8.1% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements, with a reading below 30 indicating that a stock is oversold [2]. - Nokia's current RSI reading is 19.12, indicating that the heavy selling pressure may be exhausting, and a trend reversal could be imminent [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts regarding an increase in earnings estimates for Nokia, with a 1% rise in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [7]. Group 3: Zacks Rank - Nokia holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) has faced significant selling pressure, resulting in a 10.4% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) for BTSG is currently at 23.81, indicating that the stock may be oversold and could experience a price rebound as selling pressure exhausts [5] - RSI is a momentum oscillator that helps identify whether a stock is overbought or oversold, with readings below 30 typically indicating an oversold condition [2][3] Group 2: Fundamental Indicators - There has been a strong consensus among sell-side analysts to raise earnings estimates for BTSG, leading to a 3.2% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [7] - BTSG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, suggesting a potential turnaround [8]

Group 1 - Warren Buffett's investment philosophy suggests being fearful when others are greedy and vice versa [1] - The Relative Strength Index (RSI) is a technical analysis tool used to measure stock momentum, with readings below 30 indicating oversold conditions [1] - TJX Companies' shares have an RSI reading of 29.7, indicating they are in oversold territory after trading as low as $120.1952 per share [2] Group 2 - The current RSI of the S&P 500 ETF (SPY) is 67.0, highlighting a significant difference in market sentiment compared to TJX [2] - TJX's 52-week low is $107.71 per share, while the 52-week high is $135.85, with the last trade recorded at $119.94 [4]